Scarica l'app Stockscreener
1.22
4.27%
0.05
Pre-mercato:
1.24
0.02
+1.64%
Pulmonx Corp Borsa (LUNG) Ultime notizie
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmonx Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Pulmonx Reports Q1 2026 Earnings with Strategic Outlook - Intellectia AI
Pulmonx Market Sentiment - Benzinga España
Pulmonx Corp. Revenue Breakdown – MUN:4NI - TradingView
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmonx Corp (LUNG) Cash Flow - TradingKey
TradingKey - TradingKey
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055 - TradingKey
LUNG|Pulmonx Corp|Price:1.205|Chg%:-0.015 - TradingKey
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results - Stock Titan
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz - Kalkine Media
Pulmonx Corp highlights lung device strategy as a specialized medtech player - ad-hoc-news.de
Enterprise value to EBIT forward of Pulmonx Corporation – NASDAQ:LUNG - TradingView
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to sales forward of Pulmonx Corp. – DUS:4NI - TradingView
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospe - Ad Hoc News
LUNG News | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG) - TradingView
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmonx Corp (LUNG) Institutional Confidence - TradingKey
Pulmonx Corp (LUNG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx (LUNG) awards 40,000 restricted stock units to director - Stock Titan
Director Ferrari (LUNG) awarded 40,000 Pulmonx restricted stock units - Stock Titan
Pulmonx Corp (LUNG) director granted 40,000 restricted stock units - Stock Titan
[Form 4] Pulmonx Corp Insider Trading Activity - Stock Titan
Pulmonx (LUNG) director receives 40,000-share RSU stock grant - Stock Titan
Don't Ignore The Insider Selling In Pulmonx - Sahm
Pulmonx (NASDAQ: LUNG) investors back board, auditor and executive pay - Stock Titan
Pulmonx general counsel David Lehman sells $22,474 in stock - Investing.com UK
Pulmonx general counsel David Lehman sells $22,474 in stock By Investing.com - Investing.com India
Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding - Stock Titan
Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding - Stock Titan
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan - Stock Titan
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
LUNGPulmonx Corp Stock Price and Quote - Finviz
QTEX Stock Price and Chart — NASDAQ:QTEX - TradingView
Pulmonx (LUNG) Holds Steady Near $1.54 as Key Support and Resistance Levels Define Trading RangeProtective Put - The Legal Advocate
Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung - AD HOC NEWS
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spo - AD HOC NEWS
LUNG Technical Analysis | Trend, Signals & Chart Patterns | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Why Pulmonx Corporation (LUNG) valuation makes sense when you dig deeper (Marginal Loss) 2026-05-11Buffered ETF - Newser
Pulmonx Corporation (LUNG) beats Q1 estimates with EPS improvement despite revenue growth; shares decline as investors focus on losses.AI Trading Community - Newser
Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart
0.79%
4.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):